Recent Updates
Recently added Catalysts

MK0777

Phase 2

Anxiety Disorders | Small molecule | Psychiatry |Merck & Company, Inc.|Last Updated: Nov 26, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLEDBiomarker
Total Trials1
Total Enrollment60
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00543920A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)PHASE2 COMPLETED 60Aug 1, 2002Feb 1, 2003Nov 26, 2015 -
Unlock Drug Trial Details
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
MK0777DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 70 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Diagnosis of General Anxiety Order Exclusion Criteria: * Women who are pregnant or breast-feeding * History of severe drug reaction * History of severe drug withdrawal symptoms such as seizures or delirium * Disease of cardiovascular system * Disease of the liver, kidneys, e...

Unlock Eligibility Criteria